Dr. Bernard Hamelin M.D. has more than 25 years of experience in France and abroad in the fields of clinical development and medical affairs at AstraZeneca and Sanofi pharmaceutical companies. In recent years, his work has focused on real-life health related data and digital platforms to accelerate research and clinical development and to improve the generation of evidence supporting the access and marketing of innovative molecules.
The convergence between recent discoveries in molecular and cellular biology and the digital transformation resulting from access to large amounts of health-related data has led pharmaceutical companies to revisit the planning and conduct of clinical studies. The use of these data has also made it possible to better communicate to health authorities and health care professionals the risks and benefits observed by patient sub-groups. Finally, the integration of data from various sources, such as the patient’s behaviors and preferences and the management of care systems has made it possible to develop more robust predictive models. Thanks to his experience and the links he has been able to create with institutional and private data providers and digital companies, Bernard is today considered as an expert by the industry of real-world data.
A member of the French National Society of Liver and Digestive diseases, Bernard Hamelin has acquired medical expertise in several other therapeutic areas such as immunology, oncology, rare diseases, respiratory and cardio-vascular diseases.